Summary: A new Cold Spring Harbor Laboratory (CSHL) study uncovers a striking connection between anti-cancer immunity and autoimmune brain disease. Researchers show that antibodies generated to attack tumors expressing NMDA receptors can unintentionally target the brain, causing symptoms such as psychosis and seizures.
The research centers on anti-NMDA receptor encephalitis (ANRE), the autoimmune disorder dramatized in the book Brain on Fire. The team found that some tumors—including a subset of triple-negative breast cancers—express NMDA receptor proteins normally found in the brain. When the immune system produces high-affinity antibodies to eliminate those tumor cells, some of those same antibodies can cross into the brain and disrupt normal neuronal signaling. This trade-off helps explain why certain cancer patients have unexpectedly good tumor control while developing severe neurological symptoms.
Key findings
- Hidden tumor triggers: In some cases, an apparent sudden autoimmune attack may reflect a successful immune response that identified and shrank a microscopic tumor the patient never knew existed.
- Ectopic NMDA receptor expression: NMDA receptor subunits, essential for brain signaling, were detected in some triple-negative breast cancers, making them recognizable targets for the immune system.
- Divergent antibody effects: Structural analysis showed that tumor-driven antibody maturation produces distinct antibodies that either inhibit or potentiate NMDA receptor activity in the brain.
- Clinical correlation: Approximately 15% of patients with triple-negative breast cancer carried antibodies against NMDA receptors, and these patients tended to show better cancer outcomes, indicating effective anti-tumor immunity.
Source: CSHL
Two long-standing medical puzzles — why we do not constantly develop cancer despite frequent cellular mutations, and what triggers sudden autoimmune diseases such as lupus or multiple sclerosis — may be linked by a shared immune mechanism. The CSHL team, publishing in Nature, provides evidence that germline-encoded antibodies can act as both cancer surveillance agents and, after affinity maturation, drivers of autoimmune brain disease.
Lead author Sam Kleeman, who completed his Ph.D. at CSHL, explains that seemingly spontaneous autoimmune disorders could sometimes represent the immune system’s collateral damage after it successfully detected and attacked a hidden tumor. The researchers modeled this process in mice by tracing B cell precursors present from birth through their evolution within an inducible breast tumor. As antibodies matured inside tumors, some became powerful cancer-killing molecules. Mice that mounted the strongest antibody responses experienced spontaneous tumor regression.
However, when those matured antibodies were administered into the brains of healthy mice, they induced seizures and autonomic disturbances consistent with ANRE. Cryo-electron microscopy (cryo-EM) revealed a molecular explanation: matured antibodies recognize distinct epitopes on NMDA receptor subunits and induce conformational changes that either inhibit or potentiate receptor function.
CSHL Professor Hiro Furukawa, who led the structural work, highlights that the same adaptive immune response can produce antibodies with opposing functional effects on the brain. This discovery points to the possibility of separating beneficial anti-tumor immunity from harmful neurotoxicity by selectively targeting or engineering antibody specificities.
To translate these findings toward clinical relevance, the researchers analyzed tumor samples and blood from patients with triple-negative breast cancer. They confirmed that many tumors ectopically expressed GluN1 and GluN2B NMDAR subunits and found a correlation between intratumoral NMDAR expression and circulating anti-NMDAR antibody titers. Approximately 15% of patients had anti-NMDAR antibodies, and this subgroup generally had improved clinical outcomes, consistent with active immune surveillance of NMDAR-expressing tumor cells.
CSHL Associate Professor Tobias Janowitz, who co-supervised the study, notes that understanding which antibodies drive tumor clearance and which cause neurological harm could enable the development of antibody-based therapies that preserve anti-cancer benefits while minimizing neurotoxic risk. Such targeted interventions could be especially valuable for treating triple-negative breast cancer, a subtype that currently has limited targeted therapy options.
Frequently asked questions
A: Yes. The study supports the idea that some autoimmune attacks arise after the immune system identifies and reduces a microscopic tumor. The antibodies produced to fight the tumor can persist and, in some cases, attack brain targets.
A: Cancer cells often acquire abnormal gene expression through mutation and dysregulation. Triple-negative breast cancers in particular sometimes ectopically express NMDA receptor subunits, which the immune system recognizes as foreign and attacks.
A: Not necessarily. Identifying which antibody specificities are protective versus harmful opens the door to therapies that harness anti-tumor antibodies while avoiding those that cross-react with the brain. The goal is to retain cancer-fighting benefits without triggering neurological side effects.
Editorial notes
- This article was edited by an editor with expertise in neuroscience.
- The journal paper was reviewed in full for accuracy.
- Additional context and explanation were added by the editorial staff to aid understanding.
About this neurology and cancer news
Author: Samuel Diamond
Source: CSHL
Contact: Samuel Diamond – CSHL
Image: Image credit attributed to Neuroscience News
Original research (open access):
“Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity” by Sam O. Kleeman et al., published in Nature. DOI: 10.1038/s41586-026-10278-0
Abstract
Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity
This study demonstrates that autoimmunity and anti-cancer immunity exist along a biological continuum. The paraneoplastic syndrome anti-NMDA receptor encephalitis (ANRE) exemplifies this link because intratumoral NMDAR expression correlates with the generation of anti-NMDAR antibodies. Using models of triple-negative breast cancer with inducible GluN1–GluN2B expression, the researchers show that ectopic NMDAR expression recruits B cells and drives affinity maturation. Reconstruction of intratumoral B cell lineages and cryo-EM structural analyses reveal that high-affinity, class-switched antibodies arise from pre-existing germline-configured anti-NMDAR antibodies and recognize distinct epitopes that predict inhibitory or potentiating functional effects.
Passive transfer of an NMDAR-potentiating antibody reproduced key clinical features of ANRE in healthy mice, including autonomic dysregulation and reduced seizure threshold. Clinical data link intratumoral NMDAR expression to higher anti-NMDAR antibody titers in patients with triple-negative breast cancer. Collectively, these results establish a mechanistic connection between intratumoral NMDAR expression, antibody maturation, and autoimmunity, indicating a trade-off between effective cancer immunity and the risk of neurotoxicity.